touchMDT

Case-based implementation of immune checkpoint inhibitors in endometrial cancer through shared decision making

Access to this content is not permitted for healthcare professionals based in the US.

Back to Education
Gynaecological Cancers Watch Time: 38 mins

touchMDT Case-based implementation of immune checkpoint inhibitors in endometrial cancer through shared decision making

Select a discussion in the hub to watch our multidisciplinary team share expert perspectives on the appropriate implementation of immune checkpoint inhibitors through shared decision making to ensure optimal outcomes for patients with endometrial cancer.

Overview & Learning Objectives
Gynaecological Oncologist & Medical Oncologist

A gynaecological oncologist and a medical oncologist discuss the latest data on immune checkpoint inhibitors and what they mean for patients with advanced/recurrent endometrial cancer.

Expert Spotlight
Prof. Christian Marth
Medical University Innsbruck, Innsbruck, Austria
Dr Ilaria Colombo
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

A gynaecological oncologist and a medical oncologist review the latest immunotherapy data in advanced/recurrent endometrial cancer.

Listen on the Go

Learn More Back to MDT Hub Time: 13:21
 
Gynaecological Oncologist, Medical Oncologist & Pathologist

A gynaecological oncologist, a medical oncologist and a pathologist, as a multidisciplinary team, discuss the importance of shared decision making in the management of patients with advanced/recurrent endometrial cancer.

Expert Spotlight
Prof. Christian Marth
Medical University Innsbruck, Innsbruck, Austria
Dr Ilaria Colombo
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Dr Tjalling Bosse
Leiden University Medical Center, Leiden, Netherlands

The multidisciplinary team discuss the importance of shared decision making in the management of advanced/recurrent endometrial cancer.

Listen on the Go

Learn More Back to MDT Hub Time: 10:54
 
Medical Oncologist & Gynaecological Oncologist

A medical oncologist and a gynaecological oncologist discuss the key immune-related adverse events that may be seen when treating advanced/recurrent endometrial cancer with immune checkpoint inhibitors and considerations for the individualized management of adverse events.

Expert Spotlight
Dr Ilaria Colombo
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Prof. Christian Marth
Medical University Innsbruck, Innsbruck, Austria

A medical oncologist and a gynaecological oncologist discuss the management of immune-related adverse events associated with immune checkpoint inhibitors in endometrial cancer.

Listen on the Go

 

Learn More Back to MDT Hub Time: 13:50
 
Back To Top
Learning Objectives & Overview
Overview

Join our endometrial cancer multidisciplinary team as they discuss the latest developments in an exciting era of patient management with immune checkpoint inhibitors, including important clinical considerations and testing to identify the patients who are most likely to benefit from immunotherapy, and immune-related adverse event management.

 

Learning Objectives

After watching this activity, participants should be better able to:

  • Describe the current role and rationale for immunotherapy in the treatment of advanced or recurrent endometrial cancer
  • Recognize the importance of a multidisciplinary approach for prognostic assessment and tailored treatment decisions in patients with advanced or recurrent endometrial cancer
  • Outline the safety profile and adverse event management of immune checkpoint inhibitors in patients with endometrial cancer
Faculty & Disclosures
Prof. Christian Marth

Medical University Innsbruck, Innsbruck, Austria

Professor Christian Marth is the head and professor of the Department of Obstetrics and Gynecology at Innsbruck Medical University in Austria. read more

He is the past president of the Austrian Association of Gynecologic Oncology (AGO-Austria), chair of the Ovarian Committee of Gynecologic Cancer InterGroup, council member of the European Society of Gynaecological Oncology, president of the Austrian Association of Obstetrics and Gynecology, and chair of the European Network for Gynaecological Oncological Trial groups. He is president of the AGO-Austria Study Center, and vice-president of the Austrian Breast and Colorectal Study Group.

Christian Marth is the author of more than 430 peer-reviewed articles, and he has received 13 national and international awards. He has an h-index of 76.

Prof. Christian Marth discloses: Consulting or advisory board fees from Amgen, AstraZeneca, Cerulean Pharma, GSK, MSD, Novartis, Pfizer, PharmaMar, Roche, Tesaro and Vertex Pharmaceuticals; Honoraria and expenses from Amgen, AstraZeneca, GSK, MSD, Novartis, PharmaMar, Roche and Tesaro; Research funding from AstraZeneca, EU, FWF and Roche.

Dr Ilaria Colombo

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Dr Ilaria Colombo is the disease site lead for gynaecological cancers at the Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland, and a senior physician at the New Drugs Development Unit. She specializes in the treatment of gynaecological malignancies and in early phase clinical trials for solid tumours. read more

Dr Colombo graduated with a degree in medicine and a postgraduate degree in medical oncology from the University of Milan, Italy. In 2014, she obtained a master’s degree in ‘Methodology of Clinical Research’ from the University of Parma, Italy. After establishing her clinical expertise in Italy, she improved her skills in clinical research at the Princess Margaret Cancer Centre, Toronto, Canada, focusing on new drugs development and translation research for gynaecological malignancies.

She is a principal or co-investigator in many national and international clinical trials, and is a faculty member of the ESMO Gynaecological Group and part of the core team of the Gynecological Working Group and Developmental Therapeutics Project Group of the Swiss Group for Clinical Cancer Research.

Dr Ilaria Colombo discloses: Speaker, consultancy or advisory role fees from AstraZeneca, GSK, MSD and Novartis; Travel grants from AstraZeneca, GSK, Janssen Pharmaceuticals and Tesaro; Research funding from AstraZeneca, Bayer, Incyte, MSD and Vivesto

Dr Tjalling Bosse

Leiden University Medical Center, Leiden, Netherlands

Dr Tjalling Bosse is an associate professor in the Department of Pathology at the Leiden University Medical Center (LUMC), The Netherlands. read more

He received his MD degree in 2008 from the University of Amsterdam and a PhD degree in molecular biology in 2006 from the Erasmus University in Rotterdam. He completed his pathology training at the LUMC, and specialized in gynaecologic pathology during a fellowship at the Brigham and Women’s Hospital in Boston, MA, USA, under the supervision of Prof. Dr Marisa R Nucci. Upon returning to the LUMC, he was certified as pathologist by the Royal Dutch Medical Association and became a member of staff at the department of pathology.

Dr Bosse currently leads a very active translational research programme focused on gynaecological cancers. He is the lead pathologist for two international randomized controlled clinical trials (PORTEC and RAINBO trials). His research programme currently has three active themes: improving diagnostic accuracy by integrating molecular genetic features in endometrial carcinomas; identification of novel druggable targets within the most aggressive forms of endometrial carcinoma, including a focus on exploiting homologous recombination repair; and utilizing deep learning to improve diagnostic accuracy and identify novel prognostic and predictive biomarkers. His work has had major implications on the management of endometrial and vulvar cancer patients worldwide.

Since 2013, Dr Bosse has published more than 120 articles covering a wide range of pathology-oriented, investigative and clinical peer-reviewed journals. He also plays an active role on international guideline committees for gynaecological cancers and has authored chapters of the most recent World Health Organization Classification of Tumours of Female Reproductive Organs 2020. Dr Bosse is one of the founding board members of the RAINBO programme, a new initiative that serves as an umbrella programme of clinical trials that will shape the future management of endometrial cancer patients.

Dr Tjalling Bosse discloses: Research funding from the Dutch Cancer Society and the Hanarth Fonds; Speaker fees from AstraZeneca and GSK.

Downloads
REGISTER NOW FOR FREE ACCESS TO
  • 1000+ topical and insightful peer-reviewed journal articles
  • 100+ hours of bite-sized congress highlights
  • 10 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • + Concise email updates and newsletters so you never miss out
Register For Free Now
Feedback Close
Feedback

Please provide feedback for this touchMDT on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

* = Mandatory Field

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72